PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf ·...
Transcript of PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf ·...
![Page 1: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/1.jpg)
Dr. Álvaro González
PSORIASIS Y ENFERMEDADES INFLAMATORIAS
![Page 2: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/2.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
▪ Microbiota vs microbioma
▪ Enfrentamiento entre “Buenos” y “malos”
M. Piel
M. Intestinal
“Buenos”: S. Epidermidis
“Malos”: Hongos (Malassezia…)
![Page 3: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/3.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 4: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/4.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 5: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/5.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 6: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/6.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
▪ Microbiota vs microbioma
▪ Enfrentamiento entre “Buenos” y “malos”
M. Piel
M. Intestinal
“Buenos”: S. Epidermidis
“Malos”: Hongos (Malassezia…)
“Buenos”: -Faecalibacterium prausnitzii, -Akkermansia municiphila, -Saccharomyces cerevisae
“Malos”: E.Coli
![Page 7: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/7.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 8: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/8.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 9: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/9.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 10: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/10.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 11: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/11.jpg)
Improving the course of psoriasis using themicrobiome (Hok Bing Thio)
![Page 12: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/12.jpg)
Classical systemic treatment / phototherapy in pediatric psoriasis. (Prof. Iversen)
![Page 13: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/13.jpg)
![Page 14: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/14.jpg)
![Page 15: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/15.jpg)
![Page 16: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/16.jpg)
![Page 17: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/17.jpg)
![Page 18: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/18.jpg)
![Page 19: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/19.jpg)
![Page 20: PSORIASIS Y ENFERMEDADES INFLAMATORIASeadvhighlights.aedv.es/files/pdf/psoriasis_gonzalez_2.pdf · 2019. 10. 12. · psoriasis. These patients received open-label ETN and study outcomes](https://reader033.fdocuments.in/reader033/viewer/2022060705/607163850c77294b211219d1/html5/thumbnails/20.jpg)
Psoriasis Pipeline – Potential Therapies. (K. A. Papp)